Krankheitskosten sowie gesundheitsbezogene Lebensqualität (hrQoL) bei ambulant erworbener Pneumonie (CAP) – ein systematisches Review

Zusammenfassung

Zielsetzung: Für Deutschland liegen lediglich begrenzt Daten zu den Kosten und zur gesundheitsbezogenen Lebensqualität (hrQoL) der ambulant erworbenen Pneumonie (CAP) vor. Diese Arbeit untersucht, ob sich aus der internationalen Literatur umfassendere Erkenntnisse über die Krankheitskosten der CAP und die hrQoL bei CAP generieren lassen.

Methodik: Es wurde eine systematische Literaturrecherche in elektronischen Datenbanken durchgeführt. Die Selektion der Treffer erfolgte anhand der bibliografischen Angaben. Die eingeschlossene Literatur wurde getrennt nach Krankheitskosten- bzw. hrQoL-Analysen ausgewertet.

Ergebnisse: Die Recherche ergab 172 Treffer, davon wurden 16 Publikationen zu Krankheitskosten der CAP und 5 Publikationen zu hrQoL bei CAP eingeschlossen. Lediglich zwei Publikationen sind aktuelleren Datums.

Schlussfolgerung: Es zeigt sich, dass nur wenige und veraltete Daten über die Krankheitskosten der CAP vorliegen und sich aufgrund des Studiendesigns die Studienergebnisse nicht auf Deutschland übertragen lassen. Zur Lebensqualität liegen keine verwertbaren Erkenntnisse vor, weswegen gefolgert werden kann, dass in diesem Bereich noch erheblicher Forschungsbedarf vorliegt.

Abstract

Aim: There are only very limited data available on the costs and health-related quality of life (hrQoL) of patients with community-acquired pneumonia (CAP) in Germany. The aim of this review was to identify studies in the international literature regarding the costs and hrQoL of CAP.

Method: In March 2010, a systematic literature search was performed. The acquired literature was evaluated separately for costs of illness and/or hrQoL analyses followed by a structured discussion of the findings.

Results: A total of 172 references was identified. Sixteen publications on the cost of illness for CAP and five publications on hrQoL met the selection criteria and were included in the present review.

Conclusion: There are only very limited and, furthermore, outdated data available on the costs and quality of life impacts of CAP. Hence, further research is urgently needed to fill this lack of evidence.

Literatur

• 1 Höffken G, Lorenz J, Kern W et al. Epidemiologie, Diagnostik, antimikrobielle Therapie und Management von erwachsenen Patienten mit ambulant erworbenen unteren Atemwegsinfektionen sowie ambulant erworbener Pneumonie – Update 2009.  Pneumologie. 2009;  63 e1-e68
• 2 CAPNETZ .CAP Definition und Epidemiologie. http://www.capnetz.de/html/practitioners/cap/definition Stand: 3. Januar 2011
• 3 Bartolome M, Almirall J, Morera J et al. A population-based study of the costs of care for community-acquired pneumonia.  Eur Respir J. 2004;  23 610-616
• 4 Bauer T T, Welte T, Ernen C et al. Cost analyses of community-acquired pneumonia from the hospital perspective.  Chest. 2005;  128 2238-2246
• 5 Birnbaum H G, Morley M, Greenberg P E et al. Economic burden of pneumonia in an employed population.  Arch Intern Med. 2001;  161 2725-2731
• 6 Colice G L, Morley M A, Asche C et al. Treatment costs of community-acquired pneumonia in an employed population.  Chest. 2004;  125 2140-2145
• 7 Estrada C A, Unterborn J N, Price J et al. Judging the effectiveness of clinical pathways for pneumonia: the role of risk adjustment.  Effective Clinical Practice. 2000;  3 221-228
• 8 Frei C R, Burgess D. Community-acquired pneumonia: Objective criteria to predict severe disease.  J Infect Dis Pharmacother. 2004;  6 39-48
• 9 Guest J F, Morris A. Community-acquired pneumonia: the annual cost to the National Health Service in the UK.  Eur Respir J. 1997;  10 1530-1534
• 10 Henderson A, Cleary M, Galbraith G et al. Prospective study of costs and outcome in a major adult Australian intensive care unit utilising the APACHE III severity scoring and prediction tool.  Clinical Intensive Care. 1997;  8 58-62
• 11 Kaplan V, Angus D C, Griffin M F et al. Hospitalized community-acquired pneumonia in the elderly: age- and sex-related patterns of care and outcome in the United States.  Am J Respir Crit Care Med. 2002;  165 766-772
• 12 Kruse R L, Boles K E, Mehr D R et al. The cost of treating pneumonia in the nursing home setting.  J Am Med Dir Assoc. 2003;  4 81-89
• 13 Lave J R, Fine M J, Sankey S S et al. Hospitalized pneumonia: Outcomes, treatment patterns, and costs in urban and rural areas.  Journal of General Internal Medicine. 1996;  11 415-421
• 14 Niederman M S, McCombs J S, Unger A N et al. The cost of treating community-acquired pneumonia.  Clin Ther. 1998;  20 820-837
• 15 Orrick J J, Segal R, Johns T E et al. Resource use and cost of care for patients hospitalised with community acquired pneumonia: Impact of adherence to Infectious Diseases Society of America guidelines.  PharmacoEconomics. 2004;  22 751-757
• 16 Paladino J A, Adelman M H, Schentag J J et al. Direct costs in patients hospitalised with community-acquired pneumonia after non-response to outpatient treatment with macrolide antibacterials in the US.  PharmacoEconomics. 2007;  25 677-683
• 17 Scott G, Scott H, Turley M et al. Economic cost of community-acquired pneumonia in New Zealand adults.  New Zealand Medical Journal. 2004;  117 (1196) U933
• 18 Sun H K, Nicolau D P, Kuti J L. Resource utilization of adults admitted to a large urban hospital with community-acquired pneumonia caused by Streptococcus pneumoniae.  Chest. 2006;  130 807-814
• 19 Feagan B G. A controlled trial of a critical pathway for treating community-acquired pneumonia: the CAPITAL study. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin.  Pharmacotherapy. 2001;  21 (7 Pt 2) 89S-94S
• 20 Palmer C S, Zhan C, Elixhauser A et al. Economic assessment of the community-acquired pneumonia intervention trial employing levofloxacin.  Clinical Therapeutics. 2000;  22 250-264
• 21 Marrie T J, Lau C Y, Wheeler S L et al. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin.  JAMA. 2000;  283 749-755
• 22 Carratala J F-S. Outpatient care compared with hospitalization for community-acquired pneumonia: A randomized trial in low-risk patients.  Annals of Internal Medicine. 2005;  142 165-172
• 23 Fine M J, Auble T E, Yealy D M et al. A prediction rule to identify low-risk patients with community-acquired pneumonia.  N Engl J Med. 1997;  336 243-250
• 24 Ware J E, Kosinsky M, Keller S D. SF-36 Physical and Mental Health Summary Scales: A User’s Manual.. Boston: Health Assessment Laboratory, New England Medical Center; 1994
• 25 el Moussaoui R, Opmeer B C, de Borgie C A et al. Long-term symptom recovery and health-related quality of life in patients with mild-to-moderate-severe community-acquired pneumonia.  Chest. 2006;  130 1165-1172
• 26 el Moussaoui R, Opmeer B C, Bossuyt P M et al. Development and validation of a short questionnaire in community acquired pneumonia.  Thorax. 2004;  59 591-595
• 27 Gleason P P, Kapoor W N, Stone R A et al. Medical outcomes and antimicrobial costs with the use of the American Thoracic Society Guidelines for outpatients with community-acquired pneumonia.  Journal of the American Medical Association. 1997;  278 32-39
• 28 Torres A, Muir J F, Corris P et al. Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia.  European Respiratory Journal. 2003;  21 135-143